Guardant Health (GH +25.3%) is up on 4x normal volume following its Q4 report released after the close yesterday that beat expectations. Highlights:
Revenue was up 64% to $32.9M; oncology testing revenue was up 98% to $28.1M.
Net loss was ($25.1M).
Company working with AstraZeneca on developing Guardant360 and GuardantOMNI tests as companion diagnostics for Tagrisso and Imfinzi, respectively.
2019 guidance: Revenue: $130M – 135M; net loss: ($129M – 126M).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.